CD123 Monoclonal Antibody (6H6), Super Bright™ 702, eBioscience™, Invitrogen™

Description

Description: The SB/199 monoclonal antibody reacts with mouse CD127, the high affinity a subunit of the mouse IL-7 receptor. IL-7 receptor a chain is expressed by immature B cells in the bone marrow, double-negative (CD4-/CD8-), single-positive (CD4+ and CD8+), but not double-positive (CD4+/CD8+) thymocytes. In the periphery, mature T cells express low levels of CD127. Binding of SB/199 blocks the binding of A7R34, another antibody which recognizes mouse CD127. Applications Reported: This eBioSB/199 antibody has been reported for use in flow cytometric analysis. Applications Tested: This eBioSB/199 antibody has been tested by flow cytometric analysis of mouse splenocytes. This may be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Super Bright 702 is a tandem dye that can be excited with the violet laser line (405 nm) and emits at 702 nm. We recommend using a 710/50 bandpass filter. Please make sure that your instrument is capable of detecting this fluorochrome. When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Staining Buffer (Product No.

IL-3Ra (Interleukin-3 receptor subunit alpha) belongs to the type I cytokine receptor family and is a heterodimer with a unique alpha chain paired with the common beta (beta c or CDw131) subunit. IL-3Ra is responsible for the transmission of signal of Interleukin-3. IL-3Ra and IL-3Rb chain heterodimerization is induced by Interleukin-3, which is required for receptor activation but not high affinity binding. IL-3Ra is also reported that IL-3Ra subunits are overexpressed on acute myeloid leukemia (AML) blasts compared with normal hematopoietic cells and are thus potential targets for novel therapeutic agents.